AMARIN CORPORATION PLC

Consensus Amarin Corporation plc

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Delayed Nasdaq 08:21:12 13/08/2026 pm IST			5-day change	1st Jan Change
14.24 ^USD	+1.24%		-0.18%	+2.01%

12/08	European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading	MT
30/07	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026

Evolution of the Average Target: Amarin Corporation plc

Evolution of the Target Price: Amarin Corporation plc

Changes in Analyst Recommendations: Amarin Corporation plc

2de827.pU4_YJLVqt-9krxsDXw2zxKSjtTEmcn9VJAokexRKjY.1HkOFMO6_KrHofAcTxkCllH32Zrw3LCMLadA9aQQR2TuFFQt-qb6uoj58Q~8c0357c2f7b7791dcc6790e483a09640

Analysts' recommendations: Amarin Corporation plc

27/25/27	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25/25/25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
25/23/25	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
19/23/19	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
06/23/06	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT
19/22/19	SVB Securities Adjusts Amarin's Price Target to $2 From $3, Maintains Market Perform Rating	MT
06/22/06	JPMorgan Downgrades Amarin to Underweight From Neutral	MT
05/22/05	HC Wainwright Lowers Amarin to Neutral From Buy, Price Target to $3 From $10	MT
05/22/05	SVB Leerink Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $3 From $10	MT
05/22/05	Northland Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $2 From $9	MT
16/22/16	SVB Leerink Adjusts Amarin's Price Target to $10 from $11, Maintains Outperform Rating	MT
31/22/31	SVB Leerink Adjusts Amarin's Price Target to $11 from $12, Keeps Outperform Rating	MT
12/21/12	Amarin : Goldman Sachs Downgrades Amarin to Sell From Neutral, Adjusts Price Target to $5 From $6	MT
01/21/01	Amarin : SVB Leerink Adjusts Price Target on Amarin to $16 From $12, Maintains Outperform Rating	MT
23/20/23	Amarin : Goldman Sachs Adjusts Amarin's Price Target to $6 From $8, Maintains Neutral Rating	MT
07/20/07	Amarin : Citigroup Adjusts Amarin's Price Target to $7 from $12, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMARIN CORPORATION PLC			-	-	-14.65%
	WUXI APPTEC CO., LTD.					+13.69%
	ARGENX SE					+18.14%
	INSMED INCORPORATED					+51.23%
	WUXI BIOLOGICS (CAYMAN) INC.					+4.06%
	BIONTECH SE					+29.97%
	PHARMAESSENTIA CORPORATION					-25.46%
	GENMAB A/S					+18.34%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+7.86%
	EXELIXIS, INC.					+5.08%
	Average					+10.82%
	Weighted average by Cap.					+16.07%

See all sector consensus

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

SELL

Number of Analysts

1

Last Close Price

14.06USD

Average target price

12.00USD

Spread / Average Target

-14.65%

High Price Target

12.00USD

Spread / Highest target

-14.65%

Low Price Target

12.00USD

Spread / Lowest Target

-14.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Jefferies & Co.
Northland Securities
SVB Securities LLC
JPMorgan Chase
SVB Leerink
HC Wainwright
Goldman Sachs

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

SELL

Number of Analysts

1

Last Close Price

14.06USD

Average target price

12.00USD

Spread / Average Target

-14.65%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
AMRN Stock
Consensus Amarin Corporation plc

As early as today, start finding the best investment opportunities!